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ABSTRACT
Objective: Floating bioadhesive tablets of hydrochlorothiazide were developed to prolong gastric residence time leading to an increase in drug 
bioavailability where here a combination of floating and bioadhesion mechanism is combined.
Methods: Tablets are prepared by direct compression technique using polymers xanthan gum, carbopol 974 P, HPMC K15M, HPMC K100M, magnesium 
Stearate USP-NF (Avicel PH 102), microcrystalline cellulose Ph 102, Talc, and sodium bicarbonate.
Results: Tablets were evaluated for their physical characteristics, namely, hardness, thickness, friability and weight variation, drug content, and 
floating properties. The best formulation subjected for kinetic treatment, i.e., zero order, first order, peppas, Higuchi, and Hixon-crowel. The R values 
are 0.9366, 0.9364, 0.9680, 0.9974, and 0.9283, respectively.
Conclusion: Optimized formulae F4 containing polymers HPMC K4M and CARBOPOL 974 P showed more bioadhesion with a controlled release over 
12 hrs. Therefore, formulation F4 identified as a successful formulation for the development of floating bioadhesive tablets.
Keywords: Hydrochlorothiazide, Floating tablets, Gastroretentive drug delivery system.
INTRODUCTION
Historically, oral drug administration has been the predominant 
route for drug delivery. During the past two decades, numerous oral 
delivery systems have been developed to act as drug reservoirs from 
which the active substance can be released over a defined period at a 
predetermined and controlled rate. From a pharmacokinetic point of 
view, the ideal sustained and controlled release dosage form should be 
comparable with an intravenous infusion, which supplies continuously 
the amount of drug needed to maintain constant plasma levels once the 
steady state is reached [1].
Although some important applications, including oral administration 
of peptide and protein drugs, can be used to prepare colonic drug 
delivery systems, targeting drugs to the colon by the oral route. More 
often, the drug absorption is unsatisfactory and highly variable among 
and between individuals, despite excellent in vitro release patterns. The 
reasons for this are essentially physiological and usually affected by the 
GI transit of the form, especially its gastric residence time, which appears 
to be one of the major causes of the overall transit time variability [2].
Hydrochlorothiazide is a diuretic of the benzothiadiazine class, and it 
was a very good choice drug in the management of mild to moderate 
hypertension. It inhibits sodium reabsorption in distal tubules causing 
increased excretion of sodium and water as well as potassium and 
hydrogen ions. Hydrochlorothiazide (HCTZ) is a poor water soluble 
drug having plasma half-life of 6-8 hrs and oral bioavailability is 70%. 
Its absorption window lies in the stomach therefore as long as it 
retains in the gastric environment an enhanced bioavailability can be 
seen. The present study was undertaken with the objective to develop 
an optimized fluid bed dryer containing HCTZ as a model drug to 
improve absorption and it oral bioavailability. In the current study, the 
effect of polymer (HPMC K4M, K15M, and Carbopol 974 P), polymer 
concentration and viscosity on drug release behavior and the buoyancy 
properties of prepared formulations were evaluated.
METHODS
HCTZ obtained as a gift sample from hetero laboratories Hyderabad. 
HPMC K15M, HPMC K100M, and carbopol 974 P were obtained from 
Signet Chemical Corporation, Mumbai, Avicel pH 102, Talc, Conc. 
Hydrochloric acid, Aerosil, sodium Bicarbonate, magnesium stearate 
obtained from S.D. Fine Chemicals, Mumbai.
Preparation of compression HCTZ floating tablets by direct [3-5]
All the ingredients were accurately weighed as per formula and 
dispensed in clean polythene covers. HCTZ were sifted through sieve 
No. 60. HPMC K15M, K100M, carbopol 974 P, xanthan gum, magnesium 
stearate USP-NF (Avicel PH 102), microcrystalline cellulose Ph 102, 
Talc, and sodium bicarbonate passed through sieve No. 40. After sifting 
all the above ingredients were transferred into a big polythene cover 
and mixed for 10 minutes. Then tablets are compressed in compression 
machine at specified pressure with 9 mm “B” tooling round punch 
according to the formulae given in Table 1.
Preparation of calibration curve for hydrochlorothiazide
Standard curve IN 0.1 N HCL
Accurately weighed 10 mg of drug (hydrochlorothiazide) was first 
dissolved in 10 mL of methonal in 100 mL of volumetric flask to 
make a concentration of 1000 µg/mL (primary stock solution). 1 mL 
of primary stock solution was pipetted out into 10 mL of volumetric 
flask and volume was adjusted with water to make a concentration 
of 100 µg/mL (secondary stock solution). From the secondary stock 
solution, various concentrations such as 1, 2, 3, 4, 5 …. 10 µg/mL were 
prepared for the calibration curve. A standard curve was plotted by 
taking absorbance of secondary stock solutions in ultraviolet (UV) 
double beam spectrophotometer at 272 nm.
Compatibility studies
Compatibility with excipients was confirmed by I R studies. The pure 
drug and its formulations along with excipients were subjected to IR 
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studies. In the present study, the potassium bromide disc (pellet) 
method was employed.
Evaluation of precompression blend [3,6,7]
The powder blend of all formulations was evaluated for bulk density, 
tapped density, compressibility index, Hausner ratio, and Angle of 
repose.
A. Bulk density
30 g of material was passed through a sieve No. 25 to break up 
agglomerates and introduced into a dry 100 mL cylinder, without 
compacting, the powder was carefully leveled without compacting 
and the unsettled apparent volume, V0, was read. The bulk density was 
calculated, in g/mL, using the formula.
(M)/(V0)
Where M = Total weight of the powder blend and V0 is the bulk volume 
of the powder blend.
B. Tapped density
After carrying out the procedure as given in the measurement of 
bulk density the cylinder containing the sample was tapped using 
a mechanically tapped density tester (Electrolab) that provides a 
fixed drop of 14±2 mm at a nominal rate of 300 drops/minute. The 
cylinder was tapped 500 times initially followed by an additional tap of 
750 times until difference between succeeding measurement was <2% 
and then tapped volume Vf, was measured to the nearest graduated 
unit. The tapped density was calculated, in g/mL, using the formula:
(M)/(Vf)
Where M = Total weight of the powder blend and Vf is the tapped 
volume of the powder blend.
C. Measures of powder compressibility
The compressibility index and Hausner ratio are measures of the 
propensity of powder to be compressed. As such, they are measures 
of the relative importance of inter-particulate interactions. As such, 
they are measures of the relative importance of inter-particulate 
interactions. In a free-flowing powder, such interactions are generally 
less significant, and the bulk and tapped densities will be closer in 
value. For poorer flowing materials, there are frequently greater 
interparticle interactions and a greater difference between the bulk and 
tapped densities will be observed. These differences are reflected in the 
compressibility index and the Hausner ratio, which are calculated using 
the following formulae [8-11].
Compressibility index = (Vr-V0)*100/Vr
Where Vr = tapped density; V0 = Bulk density.
D. Hausner ratio
It is the ratio of bulk density to tapped density.
V0/Vf
V0 = Bulk density; Vr = Tapped density.
E. Angle of repose
The fixed funnel method was employed to measure the repose angle. 
A funnel was secured with its tip at a given height, H above a graph 
paper that was placed on a flat horizontal surface. The blend was 
carefully pored through the funnel until the apex of the conical pile just 
touched the tip of the funnel. The radius, R, of the base of the conical 
pile was measured. The angle of repose, α, was calculated using the 
following formula.
α = tan−1 H/R
Determination of physical parameters of floating tablets [3,6,7]
Weight variation test
Totally, 20 tablets from each batch were individually weighed in grams 
on an analytical balance. The average weight and standard deviation 
were calculated, individual weight of each tablet was also calculated 
using the same and compared with average weight.
Thickness test
The thickness in millimeters (mm) was measured individually for 10 
pre-weighed tablets by using Vernier Calipers. The average thickness 
and standard deviation were reported.
Hardness test
Tablet hardness was measured using a Monsanto hardness tester. The 
crushing strength of the 10 tablets with known weight and thickness 
of each was recorded in kg/cm2 and the average hardness, and the 
standard deviation was reported.
Friability test
Totally, 20 tablets were selected from each batch and weighed. Each 
group of tablets was rotated at 25 rpm for 4 minutes (100 rotations) 
in the Roche friabilator. The tablets were then dusted and re-weighed 
to determine the loss in weight. Friability was then calculated as per 
weight loss from the original tablets.
Determination of drug content
Ten tablets with pre-determined weight from each batch were taken 
and crushed in a mortar and weight equivalent to one average tablet 
was taken, transferred to a 250 mL volumetric flask and 0.1N HCL was 
added. The volume was then made up to the mark with 0.1N HCL. The 
solution was filtered, and the filtrate was sufficiently diluted, and the 
Table 1: Composition of formulations
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
HCTZ 25 25 25 25 25 25 25 25 25 25 25 25
HPMC K 15 90 120 150 45 60 75 45 60 75 45 60 75
Carbopol 974 p 45 60 75
Xanthum gum 45 60 75
HPMC K-100 45 60 75
NaHCO3 50 50 50 50 50 50 50 50 50 50 50 50
Magnesium stearate USP-NF
(Avicel PH 102)
3 3 3 3 3 3 3 3 3 3 3 3
Talc 3 3 3 3 3 3 3 3 3 3 3 3
Microcrystalline cellulose Ph 102 Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
Total 300 300 300 300 300 300 300 300 300 300 300 300
HCTZ: Hydrochlorothiazide
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absorbance was recorded against the blank at 272 nm. The drug content 
of the standard containing the drug powder was also determined. The 





The tablet passes the requirements if the amount of the active ingredient 
in each of the 10 tested tablets lies within the range of 85-115% of the 
stated amount.
Ex-vivo bioadhesive strength [12-16]
This evaluation test was conducted for all formulations. There 
is a gradual increase in bioadhesion strength was observed in 
from F4 to F6. This is due to the increase in the concentration of 
mucoadhesive polymer carbopol 974P. Here, the study investigates 
the mucoadhesive properties of formulations from F4 to F6. 
The maximum bioadhesion strength was found for formulations 
F4-FH 6, respectively. Bioadhesion is defined as the attachment of a 
synthetic or natural macromolecule to mucus and/or an epithelial 
surface. Bioadhesion strength is depends on molecular weight and 
swelling behavior of the polymers, contact time with mucus. As the 
concentration of carbopol increased the bioadhesive strength was 
also increased, the reason for such findings might be the formation 
of secondary bioadhesion bonds with mucin and interpenetration 
of the polymer chains in the interfacial region, while other polymers 
undergo superficial bioadhesion. Bioadhesion strength values of all 
the formulations represented in Table 2.
In vitro buoyancy studies [16-20]
The in vitro buoyancy (n=3) was determined by floating lag times 
according to the method described by Rosa et al. The tablets were 
placed in a beaker containing 100 mL of 0.1N HCL. The time required 
for the tablet to rise to the surface and float was taken as floating lag 
time. Total floating time was also measured and shown in the results 
section in Table 3 and Fig. 1a-d.
In vitro drug release studies [17-24]
The release rate of hydrochlorothiazide floating tablets was 
determined using USP Type 2 apparatus. The dissolution test was 
performed in triplicate, using 900 mL of 0.1N HCL, at 37±0.5°C at 
50 rpm for 12 hrs. A 5 mL sample was withdrawn from the dissolution 
apparatus at specified time points, and the samples were replaced 
with fresh dissolution medium. The samples were filtered through 
a 0.45 µm membrane filter and diluted if necessary. The absorbance 
of these solutions was measured at 272 nm using Elico SL −159, UV-
visible spectrophotometer. The cumulative drug release was calculated 
using the equation (y = 0.03x + 0.024) generated from Beer Lambert’s 
Calibration curve in the linearity range of 1-10 µg/mL.
Kinetic analysis of dissolution data [13-17]
To analyze the in vitro release data various kinetic models were 
used to describe the release kinetics. The zero order rate equation 1 
describes the systems where the drug release rate is independent 
of its concentration. The first order equation 2 describes the release 
from a system where release rate is concentration dependent. Higuchi 
described the release of drugs from insoluble matrix as a square root 
of time dependent process based on Fickian diffusion equation 3. 
The Hixson-Crowell cube root law equation 4 describes the release 
from systems where there is a change in surface area and diameter of 
particles or tablets [13-17].
C = K0 t (1)
Where K0 is zero-order rate constant expressed in units of 
concentration/time and t is the time.
LogC = LogC0 - K1 t/2.303 (2)
Where C0 is the initial concentration of drug and K1 is the first order 
constant.
Q = KHt1/2 (3)
Where KH is the constant reflecting the design variables of the system.
Q01/3 - Qt1/3 = KHC t (4)
Where Qt is the amount of drug remained in time t, Q0 is the initial 
amount of the drug in tablet, and KHC is the rate constant for Hixson-
Crowell rate equation. Kinetic results were shown in the Table 4.
Table 2: Bioadhesive strength (n=3) of all formulations
Formulation code Bio adhesion 
strength (g)
Force of 













Table 3: In vitro buoyancy studies
Formulation code Floating lag 
time (seconds)













Fig. 1: In vitro buoyancy study of formulation F4. (a) At initial 
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Standard graph of doxofylline
The standard graph of doxofylline in 0.1N HCL showed a good linearity 
with R2 of 0.999, in the concentration range of 0-32 µg/mL at 272 nm 
shown in the Fig. 2.
Properties of the powder blend
All formulations were evaluated for compressibility index, angle of 
repose, and Hausner ratio. The results indicated the pre-compressed 
blend gas good flow shown in Table 5.
Table 4: Kinetic values obtained from in vitro released data of 
formulation F4
Kinetic model Slope R2
Zero-order plot 8.3466 0.9366
First-order plot −0.0041 0.9364
Higuchi plot 29.935 0.9974
Korsmeyer-Peppas 0.7212 0.9680
Hixon-crowel 0.0298 0.9283
Table 5: Evaluation of precompression parameters
Formulation 
code
Evaluation of precompression parameters
Bulk density (g/mL) Tapped density (g/mL) Porosity (%) Carr’s index (%) Hausner ratio Angle of repose (ᶿ)
F1 0.489 0.604 0.200 20.11 1.229 35.55
F2 0.488 0.600 0.201 19.19 1.222 33.43
F3 0.479 0.610 0.199 19.99 1.221 33.33
F4 0.482 0.607 0.207 20.12 1.122 39.61
F5 0.488 0.603 0.190 19.07 1.23 37.13
F6 0.481 0.604 0.204 20.36 1.25 32.16
F7 0.488 0.606 0.222 19.99 1.299 33.66
F8 0.545 0.704 0.225 16.25 1.194 29.14
F9 0.504 0.601 0.199 22.64 1.29 30.15
F10 0.500 0.606 0.190 21.20 1.999 28.99
F11 0.501 0.605 0.195 20.65 1.385 35.54
F12 0.535 0.607 0.204 19.91 1.229 32.89
Table 6: Evaluation of post-compression parameters
Formulation Evaluation of post-compression parameters





F1 5.51±0.01 0.23±0.05 300±2 5.12±0.02 96.28
F2 4.54±0.06 0.21±0.06 300±2 4.52±0.05 97.23
F3 4.12±0.03 0.20±0.05 300±2 4.23±0.01 99.12
F4 4.35±0.09 0.17±0.04 300±2 6.13±0.03 98.85
F5 5.42±0.02 0.19±0.03 300±2 4.0±0.06 99.54
F6 4.58±0.08 0.20±0.08 300±2 4.4±0.08 99.43
F7 4.31±0.19 0.23±0.05 300±2 4.2±0.01 98.67
F8 4.47±0.11 0.21±0.06 300±2 5.5±0.02 98.97
F9 4.49±0.14 0.20±0.05 300±2 5.3±0.04 98.28
F10 5.4±0.12 0.20±0.05 300±2 5.2±0.03 99.43
F11 4.33±0.21 0.22±0.07 300±2 4.35±0.06 98.12
F12 4.30±0.04 0.21±0.03 300±2 5.7±0.05 99.48
*Average (n=3)
Table 7: In vitro drug release study of various formulations
Time Various formulation of % drug release
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
0 0 0 0 0 0 0 0 0 0 0 0 0
0.5 13.2 10.6 9.6 15.8 12.8 11.7 13.6 11.2 9.7 12.8 11.3 9.9
1 17.3 14.8 11.7 23.1 17.6 15.1 20.7 10.3 10.2 15.6 13.5 12.6
2 20.6 16.4 12.9 31.3 21.9 18.6 28.3 14.7 12.9 19.2 17.8 14.8
3 26.9 22.9 17.3 40.8 31.9 22.7 34.5 20.9 15.7 24.9 20.8 18.7
4 37.4 34.3 23.5 47.3 39.1 29.3 40.7 26.8 21.6 35.8 31.9 28.4
5 42.1 39.1 32.6 55.1 46.9 34.4 51.6 32.8 29.1 40.7 36.3 31.8
6 54.3 44.3 38.4 62.7 51.9 41.8 58.6 37.5 36.5 52.8 41.4 38.9
7 67.5 51.6 43.7 70.4 57.6 54.4 64.4 44.6 41.6 65.2 48.8 47.6
8 73.7 59.9 57.3 76.3 64.4 58.5 69.4 51.8 54.6 72.6 57.3 53.7
9 79.2 67.7 62.9 81.9 70.6 63.4 76.2 59.8 60.4 78.3 64.7 60.8
10 82.5 74.2 69.3 86.5 77.5 69.2 81.7 67.8 67.2 81.6 70.8 69.7
11 87.8 78.5 73.1 90.9 81.6 74.3 87.2 76.5 70.6 86.5 76.3 72.3
12 90.1 81.3 78.1 98.8 87.6 80.8 94.8 83.2 78.9 90.8 84.7 73.7
*Average (n=3)
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Drug-excipient interaction studies
Fourier transform infrared spectroscopic studies (FTIR)
The FTIR spectra of drug and optimized formulation were recorded 
in Figs. 3 and 4. The characteristic peaks of the optimized formulation 
followed the same trajectory as that of the drug alone with minor 
differences. Thus, there may be no drug-excipient interactions.
Evaluation of the prepared tablets for physical parameters
All formulations were tested for physical parameter such as 
hardness, thickness, weight variation, friability, and drug content. 
All estimated parameters were found to be within the limits shown 
in Table 6.
In vitro dissolution studies
Based on the dissolution release studies keeping in view of bioadhesion 
strength formulation F4-F6 were considered to be in good floating as 
well as bioahesion property based on similarity factor with innovator 
drug dissolution profile formulae F4 were considered as optimized 
formulae dissolution release pattern observed in Table 7 and dissolution 
profiles seen in Fig. 5.
Fig. 2: Standard calibration curve of hydrochlorothiazide at λmax 
272 nm
Fig. 3: Fourier transform infrared spectrum of hydrochlorothiazide pure drug
Fig. 4: Fourier transform infrared of hydrochlorothiazide best formulation F4
Table 8: Comparison of drug profile of optimized batch with 
innovator
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with hydrochlorothizide and thus suitable for the formulation of 
hydrochlorothizide floating tablets. In vitro buoyancy studies were 
performed for all the formulations, F1-F12 by using 0.1 N HCL solution 
at 37°C. All the formulations were floated. The formulation F4-F6 
containing of HPMC K 4M and carbopol 974 P showed more Bioadhesive 
strength than other formulations. In vitro dissolution studies were 
also performed for all formulations. The formulation F4 showed the 
controlled release for 12 hrs. Thus, F4 was identified as ideal batch 
based on its results.
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Fig. 5: Dissolution profile graphs
Fig. 6: Best % drug release F4
Fig. 7: Graphical representation of dissolution profile of innovator 
versus optimized batch (F4) initially
Data treatment
From Table 8, similarity factor for F4 formulation was found to be 
more, i.e., 84.29 compared to other formulations and difference factor 
was found to be less, i.e., 16.81 compared to other formulations. 
Therefore, F4 formulation said to be comparable with that of innovator 
product where the similar matching dissolution profiles can be seen in 
Figs. 6 and 7.
CONCLUSION
From the compatibility studies, it was concluded that HPMC K15, 
K100, xanthan gum, carbopol 974 p, sodium bicarbonate, magnesium 
stearate, talc, and microcrystalline cellulose were compatible 
